Execs On The Move: Obalon Therapeutics Refreshes Board; Infab Corp Appoints New CEO
Obalon shuffles leadership as it completes merger with with ReShape Lifesciences, and Daren Dickerson, previously Infab's chief finance officer, will now manage day to day operations as chief executive officer.
You may also be interested in...
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.